Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 6898 Download: 85

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 5365 Download: 164 Web of Science: 6 Crossref: 7

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 6857 Download: 194 Web of Science: 27 Crossref: 26

Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Shiv Kumar Sarin, Shvetank Sharma

Clin Mol Hepatol. 2020;26(4):639-651. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0196

View: 9219 Download: 260 Web of Science: 11 Crossref: 12

Review

Fecal microbiota transplantation in alcohol related liver diseases

Saggere Muralikrishna Shasthry

Clin Mol Hepatol. 2020;26(3):294-301. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0057

View: 7711 Download: 230 Web of Science: 24 Crossref: 26

Microbiota, a key player in alcoholic liver disease

Anne-Marie Cassard, Dragos Ciocan

Clin Mol Hepatol. 2018;24(2):100-107. Published online December 22, 2017

DOI: https://doi.org/10.3350/cmh.2017.0067

View: 12300 Download: 532 Web of Science: 66 Crossref: 67

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Received May 10, 2024 Accepted July 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349 [Accepted]

View: 2304 Download: 775

1 |

Viewed By 5240	MAFLD: How is it different from NAFLD?
Viewed By 4998	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4905	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4673	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4650	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 162	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 136	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 120	MAFLD: How is it different from NAFLD?
Cited By 98	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search